Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity

Background: Given the overlap between envelope and polymerase in the hepatitis B virus (HBV) genome, changes in antigenic sites of the HBV surface antigen may occur as a result of selection of drug-resistance mutations. Methods: Serum HBV-DNA was isolated from 71 patients with chronic hepatitis B receiving anti-HBV drugs for longer than 12 months, 52 of whom were HIV-positive. The reverse transcriptase/envelope gene from each HBV isolate was amplified using a nested polymerase chain reaction (PCR) covering 720 bp (aa 48 to 288), which includes all known nucleos(t)ide analogue resistance mutations in HBV. Results: All but 13 patients had received lamivudine. Of the rest, 10 HBV-monoinfected subjects had received adefovir and 3 HBV/HIV-coinfected patients had been treated with tenofovir. Only lamivudine-resistance-associated mutations produced changes in the HBV envelope antigenic sites. Lamivudine resistance mutations were more frequent in HBV genotype A than D (P = 0.014). Contrary to monoinfected individuals, HBV genotype A was the predominant genotype among HBV/HIV-coinfected patients. The triple-HBV mutant rtV173L + rtL180M + rtM204V, which has been shown to produce a diminished hepatitis B surface (HBs) antigen-antibody binding, was found in 3 individuals, all coinfected with HIV and HBV. Conclusion: Circulation of HBV encoding envelope mutations with diminished HBs antigen-antibody binding as result of selection of drug-resistance mutations may occur, particularly in patients infected with HBV genotype A, the most prevalent genotype among HBV/HIV-coinfected patients. Such mutations might represent a public health concern because of the potential risk of transmission of HBV drug- and vaccine-resistant strains.

[1]  Y. Liaw,et al.  Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. , 2007, Gastroenterology.

[2]  C. Thio,et al.  Treatment of HIV/HBV coinfection: clinical and virologic issues. , 2007, AIDS reviews.

[3]  J. Villeneuve,et al.  Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. , 2006, Gastroenterology.

[4]  B. Rodés,et al.  Mutations affecting the replication capacity of the hepatitis B virus , 2006, Journal of viral hepatitis.

[5]  S. Locarnini,et al.  Antiviral drug resistance: clinical consequences and molecular aspects. , 2006, Seminars in liver disease.

[6]  M. Helm,et al.  Variant of hepatitis B virus with primary resistance to adefovir. , 2006, The New England journal of medicine.

[7]  S. Lewin,et al.  Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy , 2006, AIDS.

[8]  F. Carrat,et al.  Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV , 2006, AIDS.

[9]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[10]  R. Kaiser,et al.  Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment , 2004, AIDS.

[11]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[12]  J. Torresi.  The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  M. Manns,et al.  Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. , 2002, Virology.

[14]  D. Jackson,et al.  Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. , 2002, Virology.

[15]  M. Manns,et al.  Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. , 2002, Gastroenterology.